nach oben

Journal of Neuro-Oncology

Erschienen in:

01.02.2009 | Lab investigation - human/animal tissue

A role for the p53 pathway in the pathology of meningiomas with NF2 loss

verfasst von: ZeNan Chang, Chin-Lin Guo, Iris Ahronowitz, Anat O. Stemmer-Rachamimov, Mia MacCollin, Fabio P. Nunes

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

The neurofibromatosis 2 locus (NF2) is inactivated through mutation and loss of heterozygosity (LOH) in 40–65% of all sporadic meningiomas, while the role of the p53 tumor suppression pathway in meningioma initiation and progression is still unclear. This study aims to determine if a p53 codon 72 arginine-to-proline polymorphism, found to be correlated with cancer development and cancer patient survival in other tumors, is associated with sporadic meningioma initiation or progression. We investigated Pro72 incidence in a cohort of 92 sporadic meningiomas and analyzed its association with histological grade (WHO classification) and with NF2 LOH (determined using polymorphic microsatellite markers on 22q). The Pro72 allele was not found to be selected for in the cohort. However, in the subgroup of meningiomas with NF2 LOH and carrying Pro72, 50.0% had high grade tumors (WHO grades II and III) compared to only 14.3% of those without NF2 LOH (OR = 6.0, CI = 1.56–23.11, P = 0.012). The significant association occurred only when considering subgroups of meningiomas with or without NF2 LOH, suggesting that not including NF2 status when analyzing study cohorts may explain the variability seen in the literature where all meningiomas were grouped together. Our data suggests a role for the p53 pathway in the progression of meningiomas in which NF2 is inactivated, and highlights the importance of accounting for NF2 LOH in future studies of meningiomas and the p53 pathway.

Lantos PL, VandenBerg SR, Kleihues P (2002) Tumours of the nervous system. In: Graham DL, Lantos PL (eds) Greenfield’s neuropathology. Arnold, London

Ruttledge MH, Xie YG, Han FY et al (1994) Deletions on chromosome 22 in sporadic meningioma. Genes Chromosomes Cancer 10:122–130. doi:10.1002/gcc.2870100207 PubMedCrossRef

Ruttledge MH, Sarrazin J, Rangaratnam S et al (1994) Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 6:180–184. doi:10.1038/ng0294-180 PubMedCrossRef

Lekanne Deprez RH, Riegman PH, van Drunen E et al (1995) Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas. J Neuropathol Exp Neurol 54:224–235. doi:10.1097/00005072-199503000-00009 PubMedCrossRef

Ueki K, Wen-Bin C, Narita Y et al (1999) Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res 59:5995–5998PubMed

Nunes F, Shen Y, Niida Y et al (2005) Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma. Cancer Genet Cytogenet 162:135–139. doi:10.1016/j.cancergencyto.2005.04.003 PubMedCrossRef

Al-Mefty O, Kadri PA, Pravdenkova S et al (2004) Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J Neurosurg 101:210–218PubMed

Lamszus K (2004) Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol 63:275–286PubMed

Baker SJ, Fearon ER, Nigro JM et al (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217–221. doi:10.1126/science.2649981 PubMedCrossRef

10.

Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323–331. doi:10.1016/S0092-8674(00)81871-1 PubMedCrossRef

11.

Hollstein M, Rice K, Greenblatt MS et al (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3551–3555PubMed

12.

Das A, Tan WL, Smith DR (2005) p53 point mutation is rare in meningiomas from Singaporean patients. Asian J Surg 28:7–10PubMed

13.

Ellison DW, Lunec J, Gallagher PJ et al (1995) Accumulation of wild-type p53 in meningiomas. Neuropathol Appl Neurobiol 21:136–142. doi:10.1111/j.1365-2990.1995.tb01040.x PubMedCrossRef

14.

Ohgaki H, Eibl RH, Schwab M et al (1993) Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 8:74–80. doi:10.1002/mc.2940080203 PubMedCrossRef

15.

Pykett MJ, Landers J, George DL (1997) Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas. J Neurooncol 32:39–44. doi:10.1023/A:1005779406636 PubMedCrossRef

16.

Hei Y, Zhang XW, Wang Y, et al (2006). The features of pathology and immunohistochemistry in orbital meningiomas. Zhonghua Yan Ke Za Zhi 42:998–1001

17.

Ohkoudo M, Sawa H, Hara M et al (1998) Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas. J Neurooncol 38:41–49. doi:10.1023/A:1005946001915 PubMedCrossRef

18.

Amatya VJ, Takeshima Y, Inai K (2004) Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation. Mod Pathol 17:705–710. doi:10.1038/modpathol.3800111 PubMedCrossRef

19.

Al-Khalaf HH, Lach B, Allam A et al (2007) The p53/p21 DNA damage-signaling pathway is defective in most meningioma cells. J Neurooncol 83:9–15. doi:10.1007/s11060-006-9301-3 PubMedCrossRef

20.

Kim H, Kwak NJ, Lee JY et al (2004) Merlin neutralizes the inhibitory effect of Mdm2 on p53. J Biol Chem 279:7812–7818. doi:10.1074/jbc.M305526200 PubMedCrossRef

21.

Momand J, Zambetti GP, Olson DC et al (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237–1245. doi:10.1016/0092-8674(92)90644-R PubMedCrossRef

22.

Thut CJ, Goodrich JA, Tjian R (1997) Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev 11:1974–1986. doi:10.1101/gad.11.15.1974 PubMedCrossRef

23.

Haupt Y, Maya R, Kazaz A et al (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299. doi:10.1038/387296a0 PubMedCrossRef

24.

Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25–27. doi:10.1016/S0014-5793(97)01480-4 PubMedCrossRef

25.

Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299–303. doi:10.1038/387299a0 PubMedCrossRef

26.

Jones JM, Attardi L, Godley LA et al (1997) Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ 8:829–838PubMed

27.

Laurie NA, Donovan SL, Shih CS et al (2006) Inactivation of the p53 pathway in retinoblastoma. Nature 444:61–66. doi:10.1038/nature05194 PubMedCrossRef

28.

Bond GL, Hu W, Bond EE et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591–602. doi:10.1016/j.cell.2004.11.022 PubMedCrossRef

29.

Ku TK, Nguyen DC, Karaman M et al (2007) Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer. Mol Cancer Res 5:351–362. doi:10.1158/1541-7786.MCR-06-0238 PubMedCrossRef

30.

Erster S, Mihara M, Kim RH et al (2004) In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 24:6728–6741. doi:10.1128/MCB.24.15.6728-6741.2004 PubMedCrossRef

31.

Marchenko ND, Wolff S, Erster S et al (2007) Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J 26:923–934. doi:10.1038/sj.emboj.7601560 PubMedCrossRef

32.

Sansome C, Zaika A, Marchenko ND et al (2001) Hypoxia death stimulus induces translocation of p53 protein to mitochondria. Detection by immunofluorescence on whole cells. FEBS Lett 488:110–115. doi:10.1016/S0014-5793(00)02368-1 PubMedCrossRef

33.

Dumont P, Leu JI, Della Pietra AC 3rd et al (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365. doi:10.1038/ng1093 PubMedCrossRef

34.

Marin MC, Jost CA, Brooks LA et al (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25:47–54. doi:10.1038/75586 PubMedCrossRef

35.

Tommiska J, Eerola H, Heinonen M et al (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098–5103. doi:10.1158/1078-0432.CCR-05-0173 PubMedCrossRef

36.

Heinrich B, Hartmann C, Stemmer-Rachamimov AO et al (2003) Multiple meningiomas: investigating the molecular basis of sporadic and familial forms. Int J Cancer 103:483–488. doi:10.1002/ijc.10840 PubMedCrossRef

37.

Fan R, Wu MT, Miller D et al (2000) The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 9:1037–1042PubMed

38.

Kleihues P, Cavenee WK (eds) (2000) Pathology and genetics of tumours of the nervous system. International Agency for Research on Cancer, Lyon

39.

DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114–123. doi:10.1056/NEJM200101113440207 PubMedCrossRef

40.

Malmer B, Feychting M, Lonn S et al (2005) p53 Genotypes and risk of glioma and meningioma. Cancer Epidemiol Biomarkers Prev 14:2220–2223. doi:10.1158/1055-9965.EPI-05-0234 PubMedCrossRef

41.

Sturm I, Bosanquet AG, Hummel M et al (2005) In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer 5:105. doi:10.1186/1471-2407-5-105 PubMedCrossRef

42.

Malmer BS, Feychting M, Lonn S et al (2007) Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol 82:229–237. doi:10.1007/s11060-006-9275-1 PubMedCrossRef

43.

Biros E, Kalina I, Kohut A et al (2002) Allelic and haplotype frequencies of the p53 polymorphisms in brain tumor patients. Physiol Res 51:59–64PubMed

44.

Cahill DW, Bashirelahi N, Solomon LW et al (1984) Estrogen and progesterone receptors in meningiomas. J Neurosurg 60:985–993PubMedCrossRef

45.

Korhonen K, Salminen T, Raitanen J et al (2006) Female predominance in meningiomas cannot be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol 80:1–7. doi:10.1007/s11060-006-9146-9 PubMedCrossRef

46.

Kalamarides M, Niwa-Kawakita M, Leblois H et al (2002) Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 16:1060–1065. doi:10.1101/gad.226302 PubMedCrossRef

47.

Ozen O, Demirhan B, Altinors N (2005) Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Clin Neuropathol 24:219–224PubMed

48.

Mayo LD, Dixon JE, Durden DL et al (2002) PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277:5484–5489. doi:10.1074/jbc.M108302200 PubMedCrossRef

49.

Pomerantz J, Schreiber-Agus N, Liegeois NJ et al (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 92:713–723. doi:10.1016/S0092-8674(00)81400-2 PubMedCrossRef

50.

Sionov RV, Moallem E, Berger M et al (1999) c-Abl neutralizes the inhibitory effect of Mdm2 on p53. J Biol Chem 274:8371–8374. doi:10.1074/jbc.274.13.8371 PubMedCrossRef

Titel: A role for the p53 pathway in the pathology of meningiomas with NF2 loss
verfasst von: ZeNan Chang
Chin-Lin Guo
Iris Ahronowitz
Anat O. Stemmer-Rachamimov
Mia MacCollin
Fabio P. Nunes
Publikationsdatum: 01.02.2009
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2009
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-008-9721-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Obstipation Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2009

Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study

Nuclear survivin expression predicts poorer prognosis in glioblastoma

Molecular detection of human mammaglobin in cerebrospinal fluid from breast cancer patient with leptomeningeal carcinomatosis

DNA alkylation products formed by 1-(2-chloroethyl)-1-nitrosourea as molecular dosimeters of therapeutic response

Histone acetylation resulting in resistance to methotrexate in choroid plexus cells